Pharmacy Practice in Focus: Oncology
- July 2025
- Volume 7
- Issue 5
Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post-Progression
Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy.
Tarlatamab (Imdelltra; Amgen, Inc), a bispecific T-cell engager (BiTE) immunotherapy, meaningfully improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs) compared with chemotherapy (CTx) in patients with small cell lung cancer (SCLC) that progressed on or after initial platinum-based CTx. These observations are according to results from the phase 3 DeLLphi-304 clinical trial (NCT05740566), published by investigators in Journal of Clinical Oncology and presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.1,2